**Full Title**
Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID)

**Principal Investigator**
Debra Powell, MD

**Study Objective**
To evaluate the safety and effectiveness of canakinumab in addition to standard-of-care (SOC) procedures compared to placebo in addition to SOC procedures in adult patients with COVID-19-induced pneumonia and cytokine release syndrome (CRS).

**Inclusion Criteria**
- Male or female ≥ 18 years old
- Body weight ≥ 40 kg
- Clinically diagnosed with the SARS-CoV-2 virus within 7 days prior to randomization
- Hospitalized with COVID-19-induced pneumonia evidenced by chest x-ray or CT scan (taken within 5 days prior to randomization) with pulmonary infiltrate
- Oxygen saturation ≤ 93% on room air
- C-reactive protein ≥20 mg/L or ferritin level ≥600 μg/L

**Exclusion Criteria**
- History of hypersensitivity to canakinumab or to biologic drugs
- Intubated and on mechanical ventilation (invasive) at time of randomization
- Treatment with immunomodulators or immunosuppressant drugs
- Suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of COVID-19
- Current participation in any other investigational trials

**Affiliations & Sponsors**
Novartis

**Status**
Open to Enrollment

**Keywords**
COVID-19, SARS-CoV-2, canakinumab, pneumonia, cytokine release syndrome, CRS